近日，笔者走进了一家正被AI全方位赋能的科技型医疗企业——树兰医疗集团，试图探索今年走入第 十个年头的树兰医疗集团，在医疗AI落地应用方面的独家"密码"。 医疗AI成蓝海赛道，树兰医疗发力全链条布局 今年以来，AI赋能医疗正成为大势所趋，并走入全国各个医院实现落地应用，这条赛道已然成为新蓝 海。年初，京东健康推出了业内第一个面向医院全场景的AI产品"京东卓医"，并陆续在多家医疗机构落 地。6月，蚂蚁集团发布了AI健康应用AQ，据悉，AQ能提供健康科普、就诊咨询、健康档案等上百项 AI功能，已经连接了全国超5000家医院、近百万医生及近200位名医的AI分身。 近年来，人工智能已经逐步走进医疗行业，在健康管理、早期筛查、疾病诊断、康复护理、患者教育等 多个环节辅助诊疗，正在成为产业变革的核心驱动力，全球医疗AI市场需求也正在迅速扩张。据印度 调查公司Research Nester数据，2023年医疗保健领域的AI市场规模将超过349.2亿美元，预计到2036年底 超过4.57万亿美元，海外巨头如微软、谷歌、亚马逊均布局已久。 就国内而言，据《IDC市场报告》显示，预计到2026年，中国医疗AI市场规模将达到13 ...

智通财经APP获悉，中国银河证券发布研报称，看好2026年医药行业投资机会，近期震荡调整后估值已 回落至相对低位，有望在2026年重启升势，投资思路上寻找医药硬科技和细分赛道α，推荐关注创新药 (BIC和FIC管线龙头)、创新器械(影像、高值耗材、消费器械等)、医疗AI方向，关注医药消费复苏及独 立第三方ICL。 中国银河证券主要观点如下： 2025创新药大涨投资启示：投资医药"新"资产 2025年医药板块严重分化，3-9月多种因素持续推动创新药板块持续快速大涨，港股创新药表现更为亮 眼。中国创新药研发凭借显著的成本优势与高效的转化能力，在全球医药产业链展示出竞争优势，研发 方向上向FIC、BIC管线升级，从"技术跟随者"逐步成长为"主导参与者"，长期来看将在全球医药创新格 局中地位将持续上升。2025年创新药板块的强势上涨，是政策、产业、需求与全球化共振的结果，从创 新药、到创新器械、医疗AI，医药"新"资产依然是长期投资方向。 2026年政策展望：十五五开局之年，深化三医协同，系统性推进改革 医保支付有望从住院DRGs向门诊APGs拓展，构建全流程闭环管理以提升基金效能;创新药械将获得从 研发加速、审评审 ...

在国家"科技自立自强"战略指引下，科技创新已成为驱动经济发展的核心引擎。 作为连接科技与资本、创新与市场的桥梁，科技金融在推动科技创新驱动经济发展过程，扮演着优化创 新资源配置、提升科技成果转化效率的重要角色。 近年，众多银行积极发展科技金融，引导更多金融资源流向科技创新领域，推动中国全面提升科技自主 创新能力。 作为上海地区的重要金融机构，平安银行上海分行依托集团综合金融优势，一面聚焦集成电路、人工智 能等战略性新兴产业，构建覆盖企业全生命周期的科技金融服务体系，一面通过创新金融工具、深化产 融结合、强化科技赋能三大路径，以系统性解决方案助力广大科技企业突破发展瓶颈，为国家重大技术 攻关注入金融动能。 平安银行上海分行相关负责人表示，发展科技金融助力科技创新持续蓬勃发展，既是金融机构践行社会 责任的重要举措，也是金融机构顺应产业革新、政策调整、企业创新时代大势的主动选择。平安银行上 海分行将坚决贯彻落实国家关于科技金融的战略部署，以服务新质生产力发展为核心，全方位支持科技 型企业成长。 让科技企业不再为融资难"犯愁" 随着中国经济转型发展与国家大力扶持科技产业发展，科技产业正迎来新的发展机遇。 与此同时，国 ...

本轮融资认购金额已超5亿元。 文｜海若镜 封面来源｜企业官方 36氪独家获悉，"商汤医疗"近日完成数亿元Pre-A+轮战略融资，投资方包括联想创投、联创资本、九弦资本、申冉投资等。今年年初，商汤医疗已获得美 的系盈峰控股、人民卫生出版社集团旗下人卫科发等产业资本的上亿元投资。 据商汤医疗介绍，当前公司已启动A轮融资，投后估值超30亿元，本轮融资认购金额已超5亿元。 商汤医疗正依托AI技术，以"通专融合"为技术路径，推动"未来智慧医院"建设，其核心技术引擎包括：医疗健康大语言模型"大医"、多模态医学图像基础 模型群。 多模态医学图像基础模型群，涵盖医学图像、文本、生物信息等数据模态；可针对放射、病理等不同图像模态，实现检测、分割、分类等任务，并支持小 样本、弱标注的高效率模型训练，以突破医疗"长尾问题"数据样本少、标注难度高的瓶颈。 36氪官方公众号，期待你的关注く 为了避免陷入"软件标品"的价格战，商汤医疗搭建了智能体开发、模型应用生产双中台体系，形成"自主可控+灵活调配"的差异化优势。医院不仅能调用 底层大模型能力；还可结合自身优势，利用双中台，生产特定领域专属模型及智能体，实现智慧医院的升级。 商汤医疗C ...

近日， 商汤医疗完成 数亿元Pre-A+轮战略融资 ，投资方包括 联想创投、联创资本、九弦资本、申冉投 资等 知名机构 。今年年初，商汤医疗已获得美的系盈峰控股、人民卫生出版社集团旗下人卫科发等产业 资本的上亿元投资。 据悉，商汤医疗已启动A轮融资，投后估值超30亿元，本轮融资认购金额已超5亿元， 充分彰显了资本市 场对其发展前景的高度认可。 在技术布局上，商汤医疗以AI技术为核心支撑， 以"通专融合"为技术路径， 全力推进"未来智慧医院"建 设进程。其核心技术体系主要由两大引擎构成：一是医疗健康大语言模型"大医"，二是多模态医学图像基 础模型群，二者共同构筑起企业的技术护城河。 其中，"大医"模型以商汤日日新体系中参数规模达千亿级的"商量"大语言模型为基础，通过海量高质量医 学知识数据的训练迭代，具备了强大的感知、推理与规划能力。目前，该模型已在多个医疗细分场景实现 落地应用，涵盖智能自诊、用药咨询、影像报告结构化处理、临床辅助决策等关键环节。 多模态医学图像基础模型群，涵盖医学图像、文本、生物信息等数据模态。针对放射、病理等不同类型的 图像模态，该模型群能够精准完成检测、分割、分类等专业任务。值得一提的是 ...

投资界11月17日消息，「商汤医疗」近日完成数亿元Pre-A+轮战略融资，投资方包括联想创投、联创 资本、九弦资本、申冉投资等。今年年初，商汤医疗已获得美的系盈峰控股、人民卫生出版社集团旗下 人卫科发等产业资本的上亿元投资。 据商汤医疗介绍，当前公司已启动A轮融资，投后估值超30亿元，本轮融资认购金额已超5亿元。 因此，早在2018年，商汤医疗就提出了"赋能全院诊疗愈"的平台化理念，发展至今形成了临床诊疗、智 能决策、患者服务、医学科研等实践场景应用，覆盖医疗全流程。 这种平台化战略，也符合医院方的隐性需求。很多医院希望供应商能提供有延展性的产品，而不是装十 几款软件、对应十几家厂商。澳门镜湖医院便是一个案例，该院多年来接连采购了商汤医疗十余款人工 智能产品。 为了避免陷入"软件标品"的价格战 ，商汤医疗搭建了智能体开发、模型应用生产双中台体系，形成"自 主可控+灵活调配"的差异化优势。医院不仅能调用底层大模型能力；还可结合自身优势，利用双中 台，生产特定领域专属模型及智能体，实现智慧医院的升级。 "大医"模型，以千亿参数规模的商汤日日新"商量"大语言模型为基模，利用海量高质量医学知识数据训 练而成，具备感知 ...

6氪独家获悉，「商汤医疗」近日完成数亿元Pre-A+轮战略融资，投资方包括联想创投、联创资本、 九弦资本、申冉投资等。今年年初，商汤医疗已获得美的系盈峰控股、人民卫生出版社集团旗下人卫科 发等产业资本的上亿元投资。 这种平台化战略，也符合医院方的隐性需求。很多医院希望供应商能提供有延展性的产品，而不是装十 几款软件、对应十几家厂商。澳门镜湖医院便是一个案例，该院多年来接连采购了商汤医疗十余款人工 智能产品。 为了避免陷入"软件标品"的价格战 ，商汤医疗搭建了智能体开发、模型应用生产双中台体系，形成"自 主可控+灵活调配"的差异化优势。医院不仅能调用底层大模型能力；还可结合自身优势，利用双中 台，生产特定领域专属模型及智能体，实现智慧医院的升级。 据介绍，商汤集团实行"1+X"战略后，商汤医疗实行独立市场化运营，商业化路径逐步清晰：一方面， 继续深耕"全院智慧化"大单；另一方面，将标准化的软件模块向基层医院辐射，扩大收入规模。 "商汤做医疗已有七八年的积累，前期的投入换来了丰富的产品矩阵。独立融资，也是考虑希望引入有 资源的股东，融资并不仅仅是为了获得资金，更是为了促成合作生态。" 张少霆表示，未来将持续引入具 ...

Domestic Investment - Zhizili Technology completed seed round financing of several million yuan, led by Cloud Angel Fund, focusing on a six-dimensional force sensing solution using self-developed machine learning algorithms and fiber grating sensing technology [1] - Xiyuan Anjian announced over 200 million yuan A round financing, led by Beijing Pharmaceutical Health Industry Investment Fund, to support the key III phase clinical research of its CGRP small molecule drug BR005 [2] - Fuxin Digital completed 50 million yuan Pre-A round financing, led by Yuan Yi Capital, to enhance its AI medical solutions and expand its team [3][4] - Jiayu Medical secured several million yuan angel round financing, led by Guokai Investment, to accelerate the registration and clinical promotion of its handheld magnetic particle imaging system [5] - Fengjia Technology and Xingwang Xintong received approval for their listings on the New Third Board, focusing on chip design and integrated communication solutions respectively [6][7] - Zhizhi Chip completed seed round financing of tens of millions of yuan, focusing on high-performance operator discovery and optimization [8] - Yuntu Zhixing raised tens of millions of dollars in angel round financing, focusing on geographic information and spatial intelligence computing [9] - Yuying Trade completed 8 million yuan angel round financing, focusing on software development and brand customization [10] - Nuowan Microelectronics completed nearly 100 million yuan angel round financing, focusing on optical interconnection chips [11] - Henan Hippo Technology completed 26 million yuan angel round financing, focusing on short video social e-commerce [12] - Anxin Medical completed a significant angel round financing to enhance its gynecological diagnostic tools [13] Foreign Investment - 1Mind AI raised $30 million in A round financing, focusing on AI sales service tools [14] - Scribe completed $75 million in C round financing, with a post-financing valuation of $1.3 billion, focusing on workflow management software [15] - Onchilles Pharma raised $25 million in A1 round financing, focusing on broad-spectrum cancer treatment candidates [16] - Majestic Labs secured $100 million in A round financing, focusing on AI infrastructure for high-memory AI servers [17] - Iambic Therapeutics received $100 million in strategic investment, focusing on AI-driven medical platforms [18] - Gamma completed $68 million in B round financing, achieving a valuation of $2.1 billion, focusing on AI-generated presentations [19] IPO Queue - Real Bio submitted an IPO application, focusing on innovative drug development for antiviral and oncology treatments [20] - Mindray Medical submitted an IPO application, focusing on medical device development across multiple fields [21] - Zhongding Intelligent submitted an IPO application, focusing on customized solutions for various industries [22]

Core Insights - The report highlights the optimistic attitude of Chinese patients towards AI in healthcare, with 89% believing it enhances care quality, significantly higher than the global average of 59% [1][2] - AI is driving a transformation in China's healthcare model from "passive treatment" to "active health management," with 84% of healthcare professionals recognizing its role in early intervention [2][3] Group 1: Patient and Professional Perspectives - 90% of Chinese patients are willing to embrace technology that improves healthcare accessibility, compared to a global average of 72% [2] - 84% of Chinese healthcare professionals believe AI can play a crucial role in early intervention, and 77% think it can reduce future hospitalization rates [2][3] - Trust issues remain a challenge, with about two-thirds of patients concerned that digital technology may compromise the "human touch" in healthcare [2] Group 2: Trust Building and Systemic Challenges - The most trusted information sources for patients are doctors (96%), healthcare systems (96%), and nurses (95%) [3] - Healthcare professionals identify systemic issues such as legal liability (43%), data bias and quality (41%), and scientific validity (39%) as key areas to enhance trust [3] Group 3: AI Development and Future Trends - The demand for AI in China is described as "rigid" due to the large population and uneven distribution of medical resources [4] - Future AI systems are expected to transition from "point solutions" to "full-process coverage," particularly in imaging, requiring the development of specialized models for various medical fields [4] - Philips invests 9% of its annual revenue in innovation, with half allocated to digital and AI technologies, having registered over 1,000 AI-related intellectual properties [5] Group 4: Collaborative Ecosystem and Global Strategy - The shift in global medical innovation paradigms emphasizes the need for clinical data integration to achieve "implementable AI" [5] - Continuous policy optimization and technological iteration are positioning China as an "ecosystem builder" in healthcare AI, with a clear consensus on the necessity of technology, trust, and collaboration to reshape the future of healthcare [5]

Core Insights - Hangzhou Quanzhen Medical Technology Co., Ltd. has completed a Series B financing round of 100 million RMB, with strategic investments from Innovation Medical and Good Doctor Group expected in 2024 and 2025 respectively [2] - The company's flagship product, Trizen AI, has seen a tenfold increase in contract amounts with hospitals from January to October 2025 compared to the entire year of 2024, with an expected year-on-year growth of 12-15 times [2] Company Overview - Quanzhen Medical is one of the earliest companies in China focusing on post-training and clinical application of medical large models, aiming to enhance doctors' capabilities through AI [2] - The founder, Dr. Xue Chong, has a dual background as a clinical doctor and AI researcher, emphasizing that AI should assist rather than replace doctors [2] Product and Technology - Trizen AI is the first intelligent medical record and clinical assistance system in China, featuring automatic medical record generation, clinical decision support, and patient service [5] - The system improves medical record writing efficiency by over 65% and supports various types of medical documents, outperforming similar products in accuracy and language logic [5] - Quanzhen Medical is expanding its product from a single medical record tool to a comprehensive "AI doctor assistant" platform, covering the entire patient care process [5] Technical System - The company has established a complete "foundation-model-application" technical system since 2023, focusing on post-training methods tailored for medical scenarios [6] - Trizen AI utilizes localized large model deployment, compressing general models into specialized medical models with 1 to 10 billion parameters, significantly reducing inference costs and improving response speed [9] Commercialization - By the third quarter of 2025, Trizen AI has been widely implemented, reducing inpatient medical record writing time from an average of 10 minutes to 1.8 minutes in some hospitals, with a diagnostic accuracy rate of 93.5% [12] - The company has developed specialized models for different medical fields, including traditional Chinese medicine and pediatrics, enhancing the digital transformation of hospitals [13] Conclusion - Quanzhen Medical represents a new phase in China's medical AI landscape, transitioning from algorithm experimentation to clinical application, aiming to integrate AI capabilities with medical practice [14][15]